Self-reported Medicinal Cannabis Use as an Alternative to Prescription and Over-the-counter Medication Use Among US Military Veterans.


Journal

Clinical therapeutics
ISSN: 1879-114X
Titre abrégé: Clin Ther
Pays: United States
ID NLM: 7706726

Informations de publication

Date de publication:
Jun 2023
Historique:
received: 28 10 2022
revised: 27 03 2023
accepted: 04 04 2023
medline: 10 7 2023
pubmed: 7 7 2023
entrez: 6 7 2023
Statut: ppublish

Résumé

Mental and other physical health concerns and substance use disorder are common and co-occurring events experienced by US veterans. Treatment with medicinal cannabis is a potential alternative to unwanted medication use for veterans, but more clinical and epidemiologic research is needed to understand the risks and benefits. Data were collected from a cross-sectional, self-reported, anonymous survey asking US veterans about their health conditions, medical treatments, demographics, and medicinal cannabis use along with its self-reported effectiveness. In addition to descriptive statistics, logistic regression models were run to examine correlates of the use of cannabis as a substitution for prescription or over-the-counter medications. A total of 510 veterans of US military service participated in the survey, which was administered between March 3 and December 31, 2019. The participants reported experiencing a variety of mental and other physical health conditions. Primary health conditions reported included chronic pain (196; 38%), PTSD (131; 26%), anxiety (47; 9%), and depression (26; 5%). Most participants (343; 67%) reported using cannabis daily. Many reported using cannabis to reduce the use of over-the-counter medications (151; 30%) including antidepressants (130; 25%), anti-inflammatories (89; 17%), and other prescription medications. Additionally, 463 veterans (91% of respondents) reported that medical cannabis helped them to experience a greater quality of life and 105 (21%) reported using fewer opioids as a result of their medical cannabis use. Veterans who were Black, who were female, who served in active combat, and who were living with chronic pain were more likely to report a desire to reduce the number of prescription medications they were taking (odds ratios = 2.92, 2.29, 1.79, and 2.30, respectively). Women and individuals who used cannabis daily were more likely to report active use of cannabis to reduce prescription medication use (odds ratios = 3.05 and 2.26). Medicinal cannabis use was reported to improve quality of life and reduce unwanted medication use by many of the study participants. The present findings indicate that medicinal cannabis can potentially play a harm-reduction role, helping veterans to use fewer pharmaceutical medications and other substances. Clinicians should be mindful of the potential associations between race, sex, and combat experience and the intentions for and frequency of medicinal cannabis use.

Sections du résumé

BACKGROUND BACKGROUND
Mental and other physical health concerns and substance use disorder are common and co-occurring events experienced by US veterans. Treatment with medicinal cannabis is a potential alternative to unwanted medication use for veterans, but more clinical and epidemiologic research is needed to understand the risks and benefits.
METHODS METHODS
Data were collected from a cross-sectional, self-reported, anonymous survey asking US veterans about their health conditions, medical treatments, demographics, and medicinal cannabis use along with its self-reported effectiveness. In addition to descriptive statistics, logistic regression models were run to examine correlates of the use of cannabis as a substitution for prescription or over-the-counter medications.
FINDINGS RESULTS
A total of 510 veterans of US military service participated in the survey, which was administered between March 3 and December 31, 2019. The participants reported experiencing a variety of mental and other physical health conditions. Primary health conditions reported included chronic pain (196; 38%), PTSD (131; 26%), anxiety (47; 9%), and depression (26; 5%). Most participants (343; 67%) reported using cannabis daily. Many reported using cannabis to reduce the use of over-the-counter medications (151; 30%) including antidepressants (130; 25%), anti-inflammatories (89; 17%), and other prescription medications. Additionally, 463 veterans (91% of respondents) reported that medical cannabis helped them to experience a greater quality of life and 105 (21%) reported using fewer opioids as a result of their medical cannabis use. Veterans who were Black, who were female, who served in active combat, and who were living with chronic pain were more likely to report a desire to reduce the number of prescription medications they were taking (odds ratios = 2.92, 2.29, 1.79, and 2.30, respectively). Women and individuals who used cannabis daily were more likely to report active use of cannabis to reduce prescription medication use (odds ratios = 3.05 and 2.26).
IMPLICATIONS CONCLUSIONS
Medicinal cannabis use was reported to improve quality of life and reduce unwanted medication use by many of the study participants. The present findings indicate that medicinal cannabis can potentially play a harm-reduction role, helping veterans to use fewer pharmaceutical medications and other substances. Clinicians should be mindful of the potential associations between race, sex, and combat experience and the intentions for and frequency of medicinal cannabis use.

Identifiants

pubmed: 37414507
pii: S0149-2918(23)00133-9
doi: 10.1016/j.clinthera.2023.04.003
pii:
doi:

Substances chimiques

Medical Marijuana 0
Prescription Drugs 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

562-577

Informations de copyright

Copyright © 2023 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interest M. McNabb was executive director of C3RN at the time of this study and received less than part-time compensation for time spent on the study and the Cannabis Advancement Series (CAS). M. McNabb now is President of the Cannabis Center of Excellence and is a member of the Cannabis Advisory Board (CAB) in Massachusetts and is not financially compensated for this role on the CAB. R. MacCaffrie was the C3RN Chief Community Officer and received less than part-time compensation for participation in the study and CAS event series. A. Brum, Joint Venture & Co, received compensation for participating in the research and organizing the CAS events associated with it. S. Mandile, Joint Venture & Co, received compensation for participating in the research and organizing CAS events associated with it. The authors have indicated that they have no other conflicts of interest with regard to the content of this article.

Auteurs

Marion McNabb (M)

Cannabis Center of Excellence Inc, Boston, Massachusetts. Electronic address: marionmcnabb23@gmail.com.

Katherine A Durante (KA)

Department of Sociology, The University of Utah, Salt Lake City, Utah.

Sarah Trocchio (S)

Cannabis Center of Excellence Inc, Boston, Massachusetts; Department of Sociology and Criminology, Rider University, Lawrenceville, New Jersey.

David J Ritter (DJ)

Cannabis Center of Excellence Inc, Boston, Massachusetts.

Randal MacCaffrie (R)

Cannabis Center of Excellence Inc, Boston, Massachusetts.

Ann Brum (A)

Joint Venture & Co, Mansfield, Massachusetts.

Stephen Mandile (S)

Joint Venture & Co, Mansfield, Massachusetts.

Steven White (S)

Charlton College of Business, University of Massachusetts, North Dartmouth, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH